Skip to main content
Ildiko Lingvay, MD, Endocrinology, Dallas, TX, University of Texas Southwestern Medical Center

IldikoLingvayMDMPH, MSCS

Endocrinology • Dallas, TX

Diabetes, Obesity, Thyroid

Professor of Internal Medicine/Endocrinology at University of Texas Southwestern Medical Center, Dallas, TX

Join to view full profile

Dr. Lingvay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lingvay's full profile

Already have an account?

Summary

  • Dr. Ildiko Lingvay is an endocrinologist in Dallas, TX and is affiliated with multiple hospitals in the area, including University of Texas Southwestern Medical Center, William P. Clements, Jr. University Hospital, and Parkland Health & Hospital System. She received her medical degree from Carol Davila University of Medicine and Pharmacy and has been in practice 19 years. She specializes in diabetes, lipid metabolism, and thyroid.

Education & Training

  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
  • Texas Tech University (Permian Basin)
    Texas Tech University (Permian Basin)Residency, Internal Medicine, 1999 - 2002
  • Carol Davila University of Medicine and Pharmacy
    Carol Davila University of Medicine and PharmacyClass of 1998

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2002 - 2025
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity  
    Ildiko Lingvay, Barbara M Mcgowan, Julio Rosenstock, Marie TD Tran, Thomas A Wadden, The New England Journal of Medicine
  • A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients with Type 2 Diabetes Suboptimally Controlled on Diet and Exe...  
    Ildiko Lingvay, Cyrus V Desouza, Diabetes Care

Press Mentions

  • Type 1 Diabetes and Use of ‘Off-Label’ Drugs: Benefits, but Concerns, Too
    Type 1 Diabetes and Use of ‘Off-Label’ Drugs: Benefits, but Concerns, TooFebruary 20th, 2023
  • Study Provides a Rare View of Real-World Use of off-Label Drugs Prescribed for Type 1 Diabetes
    Study Provides a Rare View of Real-World Use of off-Label Drugs Prescribed for Type 1 DiabetesFebruary 16th, 2023
  • Ozempic Shortage: How a Weight Loss Fad Has Slashed Access to a Diabetes Drug
    Ozempic Shortage: How a Weight Loss Fad Has Slashed Access to a Diabetes DrugOctober 28th, 2022
  • Join now to see all

Grant Support

  • Role Of Pancreatic Triglycerides In Beta-Cell DysfunctionNational Center For Research Resources2007–2011

Other Languages

  • Romanian, Hungarian

Hospital Affiliations

Dr. Ildiko Lingvay, Dr. Ildiko Lingvay, MD, Dr. I Lingvay